MondegarAI
Atle Fund Management AB

Q1 2026 · 13F-HR

Atle Fund Management ABholdings as filed

Filed 2026-05-11 · accession 0001381843-26-000004

$309.7M
Reported value
39
Positions
2026-03-31
Period end
View analyzed profile →PRO

The Brief · Atle Fund Management AB · Q1 2026

AI · grounded in 13F

Atle Fund Management AB established a new position in JNJ worth $11.9M. The fund also opened new stakes in EW for $8.3M and TNGX for $3.6M. To fund these moves, the manager closed its position in UFPT, reducing exposure by $5.1M, and exited ACLXGBX for $2.7M.

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
532457108LLYELI LILLY & CO$26.8M8.67%39,722CommonSOLE
58933Y105MRKMERCK & CO. INC$22.9M7.40%33,853CommonSOLE
883556102TMOTHERMO FISHER SCIENTIFIC CORP$14.4M4.67%22,986CommonSOLE
07725L102ONCBEONE MEDICINES LTD-ADR$12.1M3.92%41,717CommonSOLE
478160104JNJJOHNSON & JOHNSON$11.9M3.86%92,377CommonSOLE
10806X102BBIOBRIDGEBIO PHARMA INC$11.9M3.84%111,363CommonSOLE
92532F100VRTXVERTEX PHARMACEUTICALS INC$11.2M3.61%22,984CommonSOLE
00287Y109ABBVABBVIE INC$10.4M3.35%108,181CommonSOLE
863667101SYKSTRYKER CORPORATION$9.6M3.09%26,835CommonSOLE
46120E602ISRGINTUITIVE SURGICAL INC$9.4M3.05%70,851CommonSOLE
462222100IONSIONIS PHARMACEUTICALS INC$9.4M3.03%27,873CommonSOLE
604749101MIRMMIRUM PHARMACEUTICALS INC$9.4M3.03%195,768CommonSOLE
126650100CVSCVS HEALTH CORP$9.3M2.99%23,773CommonSOLE
76155X100RVMDREVOLUTION MEDICINES INC$9.1M2.93%617,245CommonSOLE
101137107BSXBOSTON SCIENTIFIC CORP$8.8M2.86%40,432CommonSOLE
031162100AMGNAMGEN INC$8.7M2.81%21,903CommonSOLE
28176E108EWEDWARDS LIFESCIENCES CORP$8.3M2.67%106,518CommonSOLE
G01767105ALKSALKERMES PLC$8.2M2.66%242,473CommonSOLE
45337C102INCYINCYTE CORP$8.0M2.57%50,796CommonSOLE
64125C109NBIXNEUROCRINE BIOSCIENCES INC$7.9M2.54%89,685CommonSOLE
375558103GILDGILEAD SCIENCES INC$7.2M2.31%47,967CommonSOLE
501147102KRYSKRYSTAL BIOTECH, INC$6.8M2.19%37,579CommonSOLE
03073E105CORCENCORA INC$6.6M2.13%23,470CommonSOLE
450056106IRTCIRHYTHM TECHNOLOGIES INC$6.3M2.02%22,322CommonSOLE
457669307INSMINSMED INC$6.0M1.92%97,438CommonSOLE
N62509109NAMSNEWAMSTERDAM PHARMA CO NV$5.5M1.78%94,796CommonSOLE
15102K100CELCCELCUITY INC$5.1M1.66%141,296CommonSOLE
00370M103ABVXABIVAX SA$4.8M1.54%31,590CommonSOLE
14149Y108CAHCARDINAL HEALTH INC$4.8M1.54%108,682CommonSOLE
45166A102IDYAIDEAYA BIOSCIENCES INC$4.0M1.30%31,133CommonSOLE
87583X109TNGXTANGO THERAPEUTICS INC$3.6M1.17%29,915CommonSOLE
00773J202SYRESPYRE THERAPEUTICS INC$3.5M1.13%62,735CommonSOLE
254604101IRONDISC MEDICINE INC$3.2M1.03%107,255CommonSOLE
20454B104CMPXCOMPASS THERAPEUTICS INC$3.1M0.99%41,831CommonSOLE
91324P102UNHUNIVERSAL HEALTH SERVICES INC$2.8M0.90%14,636CommonSOLE
252131107DXCMDEXCOM INC$2.6M0.85%584,332CommonSOLE
055477103BCAXBICARA THERAPEUTICS INC$2.3M0.75%1,169,634CommonSOLE
834203309SLNOSOLENO THERAPEUTICS INC$2.2M0.71%90,184CommonSOLE
747324101PYXSPYXIS ONCOLOGY INC$1.6M0.52%197,036CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.